Like many others, I am looking forward to seeing the final IMPROVE-IT results as it will add to our basic understanding of LDL cholesterol and heart disease treatments.

FORBES: Cholesterol Drug Heart Study Continues, But Will Merck's Vytorin Really IMPROVE-IT?